Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RN2X
|
|||
| Drug Name |
PMID27841045-Compound-129
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
Korea Bio Health Co. Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H20O5
|
|||
| Canonical SMILES |
CC(=CC(=O)OC1CC2=C(C=C3C(=C2)C=CC(=O)O3)OC1(C)C)C
|
|||
| InChI |
1S/C19H20O5/c1-11(2)7-18(21)23-16-9-13-8-12-5-6-17(20)22-14(12)10-15(13)24-19(16,3)4/h5-8,10,16H,9H2,1-4H3/t16-/m0/s1
|
|||
| InChIKey |
CUKSFECWKQBVED-INIZCTEOSA-N
|
|||
| CAS Number |
CAS 5928-25-6
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:4353
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Xanthine dehydrogenase/oxidase (XDH) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Xanthine dehydrogenase/oxidase (XDH) | Target's Patent Info | [1] | |
| BioCyc | Purine nucleotides degradation | |||
| Urate biosynthesis/inosine 5'-phosphate degradation | ||||
| Guanosine nucleotides degradation | ||||
| Adenosine nucleotides degradation | ||||
| Retinoate biosynthesis II | ||||
| KEGG Pathway | Purine metabolism | |||
| Caffeine metabolism | ||||
| Drug metabolism - other enzymes | ||||
| Metabolic pathways | ||||
| Peroxisome | ||||
| Panther Pathway | Adenine and hypoxanthine salvage pathway | |||
| Purine metabolism | ||||
| Pathwhiz Pathway | Caffeine Metabolism | |||
| Purine Metabolism | ||||
| Reactome | Purine catabolism | |||
| WikiPathways | Oxidative Stress | |||
| Effects of Nitric Oxide | ||||
| Metabolism of nucleotides | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.